Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
INCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$52.81 - $83.95
Previous CloseN/A
Volume384.35K
Average Volume (3M)2.11M
Market Cap
$11.54B
Enterprise Value$9.64B
Total Cash (Recent Filing)$1.94B
Total Debt (Recent Filing)$43.12M
Price to Earnings (P/E)184.4
Beta0.53
Next Earnings
Aug 05, 2025EPS Estimate
1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.16
Shares Outstanding193,569,930
10 Day Avg. Volume1,952,559
30 Day Avg. Volume2,109,397
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda23.68
Forecast
1Y Price Target
$73.86Price Target Upside24.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Drug EfficacyNew 18 week pivotal Phase 3 data for povorcitinib in hidradenitis suppurativa demonstrates continued improvement in the primary endpoint from week 12 in both parallel trials.
Financial OutlookAnalyst's price target increased to $95, reflecting the positive financial updates and pipeline advancements.
Sales GrowthJakafi sales exceeded expectations with a 10% growth over consensus estimates, driven by significant growth in polycythemia vera patients.
Bears Say
Competition And ExclusivityOpzelura revenue will be challenged by lower tube usage and assets like povorcitinib and axatilimab will not address the Jakafi loss of exclusivity.
Market PerformanceUnderperformance of Opzelura gives pause despite topline growth ahead of expectations.
Revenue ChallengesUnderperform rating supported by analysis suggesting Opzelura revenue will be challenged by lower tube usage.
---
Ownership Overview
15.71% Insiders
21.96% Mutual Funds
0.28% Other Institutional Investors
36.48% Public Companies and
Individual Investors
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $52.81 and its highest was $83.95 in the past 12 months.
What is Incyte Corp’s market cap?
Incyte Corp’s market cap is $11.54B.
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Aug 05, 2025 which is in 88 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Apr 29, 2025. The company reported $1.16 earnings per share for the quarter, beating the consensus estimate of $0.978 by $0.182.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is 1.39.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 193,569,930 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $1.16 in its last earnings report, beating expectations of $0.978. Following the earnings report the stock price went up 1.529%.
Which hedge fund is a major shareholder of Incyte Corp?
Currently, no hedge funds are holding shares in INCY
---
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$73.86 (24.03% Upside)
$73.86 (24.03% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 75.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.22%
12-Months-Change
Fundamentals
Return on Equity
0.47%
Trailing 12-Months
Asset Growth
-19.43%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corporation is a biopharmaceutical company based in the United States, primarily focused on the discovery, development, and commercialization of proprietary therapeutics. The company's core products include treatments for oncology and inflammation, with a strong emphasis on developing small-molecule drugs and biologics that address unmet medical needs. Incyte is known for its expertise in medicinal chemistry and its robust pipeline of candidates that target various diseases.
---
INCY Company Deck
---
INCY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with significant revenue growth, successful product launches, and positive R&D progress. While there are potential challenges related to inventory management and competitive pressures, the overall sentiment remains optimistic due to the company's robust cash position and strategic planning.Read More>---
INCY Revenue Breakdown
85.33% Product revenues, net
13.66% Product royalty revenues
1.01% Milestone and contract revenues
---
INCY Stock 12 Month Forecast
Average Price Target
$73.86
▲(24.03% Upside)
Technical Analysis
---